3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Other
1
Myeloid
1
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
2
Hodgkin Disease
2
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mucositis
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Cyclophosphamide
39
fludarabine phosphate
37
Azacitidine
33
fludarabine
25
Whole-Body Irradiation
22
Busulfan
22
Tacrolimus
21
Antilymphocyte Serum
21
Mycophenolic Acid
19
Filgrastim
18
Methotrexate
16
Melphalan
15
venetoclax
13
Peripheral Blood Stem Cell Transplantation
13
Granulocyte Colony-Stimulating Factor
13
Cytarabine
13
thymoglobulin
12
Cyclosporine
12
Thiotepa
9
Cord Blood Stem Cell Transplantation
9
Alemtuzumab
8
Rituximab
7
Radiotherapy
7
Methylprednisolone
7
Decitabine
7
Clofarabine
7
Lenalidomide
6
Stem Cell Transplantation
5
Sirolimus
5
Nivolumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Myelodysplastic Syndromes
×
angiotensin I (1-7)
×
Clear all
NCT01300611
2020-12-08
USBTXA127CBT
Tarix Pharmaceuticals
Phase 1
Terminated
20 enrolled